Advancing Leukemia Management Through Liquid Biopsy: Insights into Biomarkers and Clinical Utility

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1438 - 1438

Published: April 25, 2025

Liquid biopsy is classically defined as the detection of biomarkers in bodily fluids. One these can be circulating cell-free DNA (cfDNA) released by healthy or cancer cells during apoptosis. These fragments quantified and molecularly characterized techniques like digital droplet PCR (ddPCR) next-generation sequencing (NGS). By identifying common genetic epigenetic alterations associated with specific types, cfDNA tumor (ctDNA) serve robust for monitoring initiation progression. Other biomarkers, such microRNAs (miRNAs), extracellular vesicles, (CTCs) are also applied this context. has gained attention a versatile tool diagnostics, prognosis, therapeutic monitoring, minimal residual disease (MRD) across various malignancies, including hematological cancers myeloid lymphoid leukemias. Herein, we present comprehensive review liquid usage leukemia, focus on clinical utility ctDNA, miRNAs, exosomes treatment response, tracking clonal evolution, detecting disease. Our emphasizes translational implications tools improving patient outcomes outlines current challenges their integration into practice.

Language: Английский

Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 26, 2024

Malignant tumors of the hematologic system have a high degree malignancy and mortality rates. Chimeric antigen receptor T cell (CAR-T) therapy has become an important option for patients with relapsed/refractory tumors, showing astonishing therapeutic effects thus, it brought new hope to treatment malignant system. Despite significant CAR-T, its toxic reactions, such as Cytokine Release Syndrome (CRS) Immune Effector Cell-Associated Neurotoxicity (ICANS), cannot be ignored since they can cause damage multiple systems, including cardiovascular We summarize biomarkers related prediction, diagnosis, efficacy, prognosis, further exploring potential monitoring indicators toxicity prevention. This review aims CAR-T on cardiovascular, hematologic, nervous well biomarkers, explore preventing toxicity, thereby providing references clinical regulation assessment effects.

Language: Английский

Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future

Blood Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 101237 - 101237

Published: Sept. 1, 2024

Language: Английский